Posts tagged Vaughn Embro-Pantalony
Microbix appoints Cameron Groome as President, CEO

Microbix Biosystems (TSX:MBX) has appointed Cameron Groome as its president and CEO, with Vaughn Embro-Pantalony retiring from those positions but remaining an executive director, working closely with Mr. Groome to ensure a smooth leadership transition.

Read More
Microbix meets FDA on Kinlytic return to U.S. market

Microbix Biosystems (TSX:MBX) has consulted with the FDA regarding the company's plans to return its thrombolytic biologic drug, Kinlytic, to the U.S. market.

Read More
Microbix posts 84% jump in Q1 revenue

Microbix Biosystems (TSX:MBX) reported that revenue rose 84% to almost $2-million for the first quarter ended Dec. 31, 2016, from $1.1-million a year earlier.

Read More
Microbix in Asia Pacific distribution pact with Meridian

Microbix Biosystems (TSX:MBX) has signed a distribution agreement with Meridian Life Science, a wholly owned unit of Meridian Bioscience (NASDAQ:VIVO), a fully integrated global diagnostic and life sciences company.

Read More
Microbix Q4 revenue jumps 64% to new record

Sales for Microbix Biosystems (TSX:MBX) in the fourth quarter of fiscal 2016 climbed 64% to $3.5-million, representing the highest quarterly revenue ever achieved by the company, from $2.1-million a year earlier.

Read More
Microbix names Jim Currie as CFO

Microbix Biosystems (TSX:MBX) appointed Jim Currie as CFO, succeeding Charles Wallace, who is retiring at the end of the year.

Mr. Currie was most recently CFO of SMTC, a global electronics manufacturing services company. Previously, he was VP of finance at MDS SCIEX, a global leader in life science and analytical technologies.

Read More
Microbix Q4 preliminary revenue up 57%

Microbix Biosystems (TSX:MBX) expects to report revenue in the range of $3.3-million for the fiscal fourth quarter ended Sept. 30, 2016, an increase of 57% from $2.1-million in the year earlier quarter.

Fourth quarter virology revenue is expected to be in the range of $3.3-million, up 106%, compared with $1.6-million in the fourth quarter of fiscal 2015.

Read More
Microbix sees record sales in fiscal 2016

Microbix Biosystems (TSX:MBX) expects a strong performance over the rest of the fiscal year based on indicated customer demand, leading the company to project record sales for the current fiscal year, ending Sept. 30.

“Thus far, sales for the second quarter are in line with such full-year expectations,” Vaughn Embro-Pantalony, president and CEO, said in the first quarter earnings report.

Read More